Nonalcoholic steatohepatitis in nonalcoholic fatty liver disease patients of Bangladesh

被引:0
|
作者
Shahinul Alam [1 ]
Sheikh Mohammad Noor-E-Alam [1 ]
Ziaur Rahman Chowdhury [1 ]
Mahabubul Alam [1 ]
Jahangir Kabir [1 ]
机构
[1] Department of Hepatology,Bangabandhu Sheikh Mujib Medical University,Shahbag,Dhaka 1000,Bangladesh
关键词
Fatty liver; Gamma-glutamyl transpeptidase; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Alanine aminotransferase; Obesity; Basal metabolic index;
D O I
暂无
中图分类号
R575.1 [肝炎];
学科分类号
1002 ; 100201 ;
摘要
AIM: To explore the prevalence and risk factors for nonalcoholic steatohepatitis (NASH) in nonalcoholic fatty liver disease (NAFLD) patients. METHODS: We have included 493 patients with sonographic evidence of a fatty change, and 177 of these individuals were evaluated and confirmed after liver biopsy. The exclusion criteria consisted of significant alcohol abuse (< 20 g daily), evidence of hepatitis B and C, evidence of drug-induced fatty liver disease and other specific liver diseases such as hemochromatosis, Wilson’s disease or autoimmune liver disease. The patients were assessed for metabolic syndrome, and biochemical, anthropometric and histopathological evaluations were carried out. The degree of disease activity in the NAFLD patients was evaluated using the NAFLD Activity Score. The data were analyzed by SPSS, version 16.0. RESULTS: Females predominated among the study participants (250, 57.0%), and the mean age was 40.8 ± 10.2 years. The numbers of overweight, obeseⅠ and obese Ⅱ patients were 58 (13.2%), 237 (53.9%) and 93 (21.2%), respectively. However, there were 422 (96.2%) centrally obese patients. NASH was absent in 10 (5.6%) cases, borderline in 92 (52.6%) cases and present in 75 (42.4%) cases. The presence of diabetes could significantly (P = 0.001) differentiate NASH from simple steatosis. The following parameters did not influence the development of NASH: age, sex, basal metabolic index, waist circumference, serum high-density lipoprotein, triglyceride, insulin resistance index, hypertension and metabolic syndrome. The serum gammaglutamyl transpeptidase (GGT) level was significantly higher (P = 0.05, 51.7 ± 32.8 and 40.4 ± 22.6 U/L) in the NASH patients, with a sensitivity of 45% and a specificity of only 68%. The serum alanine aminotransferase and aspartate aminotransferase levels were not able to predict NASH. CONCLUSION: Females were the predominant sufferers of NAFLD in Bangladesh. The prevalence of NASH was high. Diabetes was found to be the main culprit in developing NASH. GGT was the only biochemical marker of NASH. We recommend liver biopsy in NAFLD patients who have diabetes and elevated GGT.
引用
收藏
页码:281 / 287
页数:7
相关论文
共 50 条
  • [21] The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
    Kazankov, Konstantin
    Jorgensen, Simon Mark Dahl
    Thomsen, Karen Louise
    Moller, Holger Jon
    Vilstrup, Hendrik
    George, Jacob
    Schuppan, Detlef
    Gronbaek, Henning
    [J]. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2019, 16 (03) : 145 - 159
  • [22] The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
    Konstantin Kazankov
    Simon Mark Dahl Jørgensen
    Karen Louise Thomsen
    Holger Jon Møller
    Hendrik Vilstrup
    Jacob George
    Detlef Schuppan
    Henning Grønbæk
    [J]. Nature Reviews Gastroenterology & Hepatology, 2019, 16 : 145 - 159
  • [23] Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
    Takahashi, Yoshihisa
    Soejima, Yurie
    Fukusato, Toshio
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2012, 18 (19) : 2300 - 2308
  • [24] Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
    Gawrieh, Samer
    Chalasani, Naga
    [J]. CLINICS IN LIVER DISEASE, 2018, 22 (01) : 189 - +
  • [25] Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
    Imajo, Kento
    Yoneda, Masato
    Kessoku, Takaomi
    Ogawa, Yuji
    Maeda, Shin
    Sumida, Yoshio
    Hyogo, Hideyuki
    Eguchi, Yuichiro
    Wada, Koichiro
    Nakajima, Atsushi
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2013, 14 (11) : 21833 - 21857
  • [26] Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
    Golabi, Pegah
    Bush, Haley
    Younossi, Zobair M.
    [J]. CLINICS IN LIVER DISEASE, 2017, 21 (04) : 739 - 753
  • [27] Radiologic Imaging in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
    Esterson, Yonah B.
    Grimaldi, Gregory M.
    [J]. CLINICS IN LIVER DISEASE, 2018, 22 (01) : 93 - +
  • [28] Pathological findings of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
    Sakamoto, Michiie
    Tsujikawa, Hanako
    Effendi, Kathryn
    Ojima, Hidenori
    Harada, Kenichi
    Zen, Yoh
    Kondo, Fukuo
    Nakano, Masayuki
    Kage, Masayoshi
    Sumida, Yoshio
    Hashimoto, Etsuko
    Yamada, Gotaro
    Okanoue, Takeshi
    Koike, Kazuhiko
    [J]. PATHOLOGY INTERNATIONAL, 2017, 67 (01) : 1 - 7
  • [29] Noninvasive Evaluation for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
    Kogachi, Shannon
    Noureddin, Mazen
    [J]. CLINICAL THERAPEUTICS, 2021, 43 (03) : 455 - 472
  • [30] Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
    Younossi, Zobair
    Tacke, Frank
    Arrese, Marco
    Sharma, Barjesh Chander
    Mostafa, Ibrahim
    Bugianesi, Elisabetta
    Wong, Vincent Wai-Sun
    Yilmaz, Yusuf
    George, Jacob
    Fan, Jiangao
    Vos, Miriam B.
    [J]. HEPATOLOGY, 2019, 69 (06) : 2672 - 2682